Currently, the company's two investigational compounds, ublituximab and umbralisib (the combination of which is referred to as U2) are in Phase 3 clinical development for patients suffering from hematologic malignancies, with ublituximab also in Phase 3 clinical development for multiple sclerosis. Shares spiked 41% on Dec. 10 as the company announced positive results from its Ultimate I and II Phase 3 studies evaluating Ublituximab monotherapy for multiple sclerosis treatment. TG Therapeutics disclosed that both studies met their primary endpoints, with ublituximab demonstrating a statistically significant reduction in annualized relapse rate over a 96-week period.